1-{[3-(3-methanesulfonylpropoxy)phenyl]methyl}-5-{5-(4-trifluoromethanesulfonylphenyl)-1,2,4-oxadiazol-3-yl}-1,2-dihydropyridin-2-one | 1571028-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-{[3-(3-methanesulfonylpropoxy)phenyl]methyl}-5-{5-(4-trifluoromethanesulfonylphenyl)-1,2,4-oxadiazol-3-yl}-1,2-dihydropyridin-2-one
• 英文别名: 1-[[3-(3-Methylsulfonylpropoxy)phenyl]methyl]-5-[5-[4-(trifluoromethylsulfonyl)phenyl]-1,2,4-oxadiazol-3-yl]pyridin-2-one
• CAS: 1571028-73-3
• 化学式: C₂₅H₂₂F₃N₃O₇S₂
• 分子量: 597.593
• InChiKey: LZRRMXVCFUBVII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  154
• 氢给体数：
  0
• 氢受体数：
  12

文献信息

• HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center

  公开号：US20140073634A1

  公开（公告）日：2014-03-13

  The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.